Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

France's ANSM Moves Paracetamol, Ibuprofen And Aspirin Behind The Counter

French medicines agency takes action over safety concerns

Executive Summary

France restricts sales of medicines containing paracetamol, ibuprofen and aspirin to behind the pharmacy counter due to safety concerns.

You may also be interested in...



NZ To Tighten Paracetamol Safety Warnings

New Zealand is the latest regulatory body to take action over the hepatic risks of the widely used painkiller paracetamol.

Australia Rejects Hair-Loss Switch, Up-Schedules Modified-Release Paracetamol

Australia has rejected an application to switch an oral hair-loss treatment, while also up-scheduling modified release paracetamol over safety concerns.

France Orders On-Pack Warnings For Paracetamol Over Liver Damage Fears

Fears over misuse mean all paracetamol-containing products (also known as acetaminophen) sold in France will from next year be required to carry prominent on-pack warnings.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC031354

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel